

IPSEN IN BRIEF

2022

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.



DIANA
Living with post-stroke spasticity
Sintra, Portugal

OUR STRATEGY

Focus. Together.
For patients & society



Maximize our brands

Drive efficiencies

Strengthen pipeline

Focus on culture

CSR STRATEGY

2024 AMBITIONS

Employees

- Best place to work certification in **>75%** of countries
- Gender balance in global leadership team
- Fill **65%** of leadership roles via internal promotion

Environment

- **21%** reduction of greenhouse gas emissions
- **24%** reduction of water consumption
- **20%** reduction of process waste

Communities

- More than **1/3** of employees supporting healthcare and environment communities
- Continue support for IFPMA Access Accelerated initiative

IPSEN KEY FIGURES A

€2.6bn*

TOTAL SALES (2021)
* EXCLUDING CONSUMER HEALTHCARE BUSINESS (CHC)

4,500+

COLLEAGUES

100+

COUNTRIES WHERE IPSEN MEDICINES ARE MARKETED

12

MEDICINES

The Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs:

Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

THERAPEUTIC AREAS

ONCOLOGY

More than **35 years of research in Oncology** focusing on cancers with high unmet needs



RARE DISEASE

Teams of **global experts and researchers** developing life-changing treatments for **Rare Diseases**


PALOVAROTENE

NEUROSCIENCE

More than **25 years of Neuroscience expertise and innovation**



2021 TOTAL SALES AND GROWTH*




GEOGRAPHIC BREAKDOWN

Total sales by region: 2021*
excluding CHC business

35%
NORTH AMERICA

31%
EUS

34%
REST OF THE WORLD



FINANCIAL OUTLOOK* 2020 TO 2024



Total sales
CAGR to 2024
between **+4% & +6%**



Commitment to invest
in R&D, supported
by SG&A efficiencies



€3.5bn cumulative
remaining firepower for
pipeline expansion



Craig Marks, Vice President,
Investor Relations
+44 (0) 7584 349 193



Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 (0) 6 64 26 17 49

investor.relations@ipsen.com
ipsen.com/investors



*All growth rates are at constant exchange rates. Cumulative firepower by 2024 as at the end of 2021.